Naito R, Takeuchi M, Morihira K, Hayakawa M, Ikeda K, Shibanuma T, Isomura Y
Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., Ibaraki, Japan.
Chem Pharm Bull (Tokyo). 1998 Aug;46(8):1286-94. doi: 10.1248/cpb.46.1286.
A novel series of biphenylylcarbamate derivatives were synthesized and evaluated for binding to M1, M2 and M3 receptors and for antimuscarinic activities. Receptor binding assays indicated that biphenyl-2-ylcarbamate derivatives had high affinities for M1 and M3 receptors and good selectivities for M3 receptor over M2 receptor, indicating that the biphenyl-2-yl group is a novel hydrophobic replacement for the benzhydryl group in the muscarinic antagonist field. In this series, quinuclidin-4-yl biphenyl-2-ylcarbamate monohydrochloride (8l, YM-46303) exhibited the highest affinities for M1 and M3 receptors, and selectivity for M3 over M2 receptor. Compared to oxybutynin, YM-46303 showed approximately ten times higher inhibitory activity on bladder pressure in reflexly-evoked rhythmic contraction, and about 5-fold greater selectivity for urinary bladder contraction against salivary secretion in rats. Moreover, selective antagonistic activity was also observed in vitro. Further evaluation of antimuscarinic effects on bradycardia and pressor in pithed rats, and on tremor in mice, showed that YM-46303 can be useful for the treatment of urinary urge incontinence as a bladder-selective M3 antagonist with potent activities and fewer side effects.
合成了一系列新型联苯氨基甲酸酯衍生物,并对其与M1、M2和M3受体的结合以及抗毒蕈碱活性进行了评估。受体结合试验表明,联苯-2-基氨基甲酸酯衍生物对M1和M3受体具有高亲和力,对M3受体相对于M2受体具有良好的选择性,这表明联苯-2-基是毒蕈碱拮抗剂领域中苄基的一种新型疏水取代基。在该系列中,喹核-4-基联苯-2-基氨基甲酸酯盐酸盐(8l,YM-46303)对M1和M3受体表现出最高的亲和力,以及对M3受体相对于M2受体的选择性。与奥昔布宁相比,YM-46303在反射诱发的节律性收缩中对膀胱压力的抑制活性高约10倍,对大鼠膀胱收缩相对于唾液分泌的选择性高约5倍。此外,在体外也观察到了选择性拮抗活性。对去脑大鼠的心动过缓和升压以及对小鼠震颤的抗毒蕈碱作用的进一步评估表明,YM-46303作为一种具有强效活性和较少副作用的膀胱选择性M3拮抗剂,可用于治疗急迫性尿失禁。